V
Power Law company profile
Viridian Therapeutics
Biotech & Life Sciences · Boulder, United States · Founded 2007 · IPO 2017 Unicorn
Valuation
$637M
Market cap · Apr/2026
Revenue
$71M
Latest reported FY
Global footprint
Where Viridian Therapeutics has talent and traffic
AI talent share
0.4%
of workforce is AI talent
(1 of 278 staff)
(1 of 278 staff)
Core AI00%
Other AI10.36%
Non-AI workforce27799.64%
Web traffic by country
12K
monthly visits
across markets
across markets
🇺🇸 United States76.7%
🇬🇧 United Kingdom12.5%
🇮🇳 India10.8%
🇨🇦 Canada0.8%
Patent intelligence
$57M patent portfolio · 32 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$57M
8.9% of market cap · 2.9× smaller than top peer Amicus Therapeutics ($164M)
32 active patent families
Where Viridian Therapeutics innovates
PharmacologyMedicinal chemistryPharmaceutical medicineDiseasePharmaceutical drug
Below peer median on Strategic
Quality vs same-sector peers
Viridian Therapeutics on the five Patsnap quality dimensions
Viridian Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Viridian Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Viridian Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Viridian Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.